AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29651953 — intervention group
Group type: EXPERIMENTAL
Intervention: Partly supervised cardiac rehabilitation (G1)
Number of subjects: 61
Study 29651953 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised cardiac rehabilitation (G2)
Number of subjects: 61
Study 27754709 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-Modified Ginseng Extract (EMGE) 2,000 mg/day for 4 weeks
Number of subjects: 52
Study 27754709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 24038817 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional stenting for side branch dissections
Number of subjects: 117
Study 24038817 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (no stenting) for side branch dissections
Number of subjects: 117
Study 24038817 — intervention group
Group type: COMPARATOR
Intervention: Patients without side branch dissections
Number of subjects: 117
Study 23363720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (4 CAD lectures, CAD outpatient visit twice a month, monthly telephone instructions)
Number of subjects: 263
Study 23363720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 263
Study 20728691 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualizing student instruction (ISI)
Number of subjects: 445
Study 20728691 — intervention group
Group type: COMPARATOR
Intervention: Control group (business-as-usual)
Number of subjects: 445
Study 18264012 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous histamine (1‐10 ng twice a week)
Number of subjects: 90
Study 18264012 — intervention group
Group type: COMPARATOR
Intervention: Oral topiramate (100 mg daily)
Number of subjects: 90
Study 19841763 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency ultrasonic agitation applied with a 1 MHz therapeutic ultrasonic device on the dentin surfaces using G-Bond adhesive.
Number of subjects: 36
Study 19841763 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency ultrasonic agitation applied with a 1 MHz therapeutic ultrasonic device on the dentin surfaces using Futurabond adhesive.
Number of subjects: 36
Study 19841763 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency ultrasonic agitation applied with a 1 MHz therapeutic ultrasonic device on the dentin surfaces using Clearfil S3 Bond adhesive.
Number of subjects: 36
Study 19841763 — intervention group
Group type: COMPARATOR
Intervention: Control group using bonding procedures according to manufacturers' instructions for G-Bond adhesive.
Number of subjects: 36
Study 19841763 — intervention group
Group type: COMPARATOR
Intervention: Control group using bonding procedures according to manufacturers' instructions for Futurabond adhesive.
Number of subjects: 36
Study 19841763 — intervention group
Group type: COMPARATOR
Intervention: Control group using bonding procedures according to manufacturers' instructions for Clearfil S3 Bond adhesive.
Number of subjects: 36
Study 15206986 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (10 mg) administered in fasting state
Number of subjects: 24
Study 15206986 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin (10 mg) administered in fed state
Number of subjects: 24
Study 11324372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 2100
Study 11324372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2100
Study 9134633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (INR 2.5-4.0)
Number of subjects: 0
Study 9134633 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration (APTT 1.5-2.5 x control)
Number of subjects: 0
Study 9134633 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated subjects with congenital antithrombin deficiency
Number of subjects: 0
Study 9134633 — intervention group
Group type: EXPERIMENTAL
Intervention: Women using oral contraceptives
Number of subjects: 0
Study 9134633 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep vein thrombosis (phlebographically confirmed)
Number of subjects: 0
Study 9134633 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease (angiographically assessed)
Number of subjects: 0
Study 7898965 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy (two doses of Exosurf rescue surfactant)
Number of subjects: 10
Study 7898965 — intervention group
Group type: COMPARATOR
Intervention: Air placebo (two doses of air)
Number of subjects: 10
Study 3112934 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin levels above the MIC of alfa-streptococci
Number of subjects: 0
Study 3112934 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin levels above the MIC of beta-streptococci but below that of alfa-strains
Number of subjects: 0
Study 3112934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary sugar coated penicillin tablets
Number of subjects: 0
Study 30666859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioptron light treatment in addition to full mouth scaling and root planing (FMSRP)
Number of subjects: 40
Study 30666859 — intervention group
Group type: COMPARATOR
Intervention: Full mouth scaling and root planing (FMSRP)
Number of subjects: 40
Study 29157258 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs and eye mask
Number of subjects: 64
Study 29157258 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs and eye mask (when worn all night)
Number of subjects: 64
Study 29157258 — intervention group
Group type: COMPARATOR
Intervention: Control (no earplugs and eye mask)
Number of subjects: 64
Study 26188623 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 23608139 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper respiratory tract illness (URTI) with high stress exposure
Number of subjects: 356
Study 23608139 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper respiratory tract illness (URTI) with low stress exposure
Number of subjects: 356
Study 23608139 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (no URTI)
Number of subjects: 356
Study 21157021 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg bid)
Number of subjects: 49
Study 21157021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 18984667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg daily for 6 months
Number of subjects: 23
Study 18984667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16505499 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 or 1,000 mcg chromium daily (chromium picolinate)
Number of subjects: 46
Study 16505499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 14765284 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-santalol
Number of subjects: 0
Study 14765284 — intervention group
Group type: EXPERIMENTAL
Intervention: East Indian sandalwood oil
Number of subjects: 0
Study 11757828 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 L fill volume
Number of subjects: 21
Study 11757828 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 L fill volume
Number of subjects: 21
Study 9153171 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 110
Study 9153171 — intervention group
Group type: COMPARATOR
Intervention: Open Nissen fundoplication
Number of subjects: 110
Study 7957545 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 15 mg daily
Number of subjects: 7
Study 7957545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3664330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg twice daily)
Number of subjects: 51
Study 3664330 — intervention group
Group type: COMPARATOR
Intervention: Nystatin (500,000 units four times daily)
Number of subjects: 51
Study 29517578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 0
Study 29517578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27621237 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 351
Study 27621237 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 351
Study 25007860 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 270
Study 25007860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 22388343 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (0.8 mg)
Number of subjects: 18
Study 22388343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol (8 mg)
Number of subjects: 18
Study 20029224 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin continued throughout pregnancy
Number of subjects: 197
Study 20029224 — intervention group
Group type: COMPARATOR
Intervention: Control group (Metformin stopped in first trimester or conceived spontaneously without Metformin)
Number of subjects: 197
Study 20029224 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin continued in women with prior history of miscarriage
Number of subjects: 197
Study 20029224 — intervention group
Group type: COMPARATOR
Intervention: Control group (women with prior history of miscarriage)
Number of subjects: 197
Study 18299779 — intervention group
Group type: EXPERIMENTAL
Intervention: heroin+methadone group
Number of subjects: 2
Study 18299779 — intervention group
Group type: EXPERIMENTAL
Intervention: methadone-only group
Number of subjects: 2
Study 18299779 — intervention group
Group type: COMPARATOR
Intervention: non-users
Number of subjects: 2
Study 16222412 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Glucose Awareness Training (BGAT) for 2 months
Number of subjects: 111
Study 16222412 — intervention group
Group type: COMPARATOR
Intervention: Physician-guided self-help control intervention
Number of subjects: 111
Study 12490966 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide with isoproterenol
Number of subjects: 13
Study 12490966 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol alone
Number of subjects: 13
Study 9585236 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen delivered in a transgenic potato
Number of subjects: 0
Study 9585236 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected antigen from transgenic plants
Number of subjects: 0
Study 9585236 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant tissues fed to mice
Number of subjects: 0
Study 7562029 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy in group A (moderate pain)
Number of subjects: 200
Study 7562029 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy in group B (severe pain)
Number of subjects: 200
Study 7562029 — intervention group
Group type: COMPARATOR
Intervention: Automated percutaneous discectomy
Number of subjects: 200
Study 2635228 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm imagery
Number of subjects: 32
Study 2635228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold imagery
Number of subjects: 32
Study 2635228 — intervention group
Group type: COMPARATOR
Intervention: Neutral imagery
Number of subjects: 32
Study 2635228 — intervention group
Group type: COMPARATOR
Intervention: No-imagery
Number of subjects: 32
Study 788732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralidoxime mesylate (P2S) 750 mg and atropine sulphate 2.0 mg
Number of subjects: 44
Study 788732 — intervention group
Group type: COMPARATOR
Intervention: Pralidoxime mesylate (P2S) alone
Number of subjects: 44
Study 30061531 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (stimulation with the developed device)
Number of subjects: 13
Study 30061531 — intervention group
Group type: COMPARATOR
Intervention: Control condition (stimulation with static non‐interoceptive pressure)
Number of subjects: 13
Study 27093162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 160
Study 27093162 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 160
Study 25213055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg daily for 6 weeks
Number of subjects: 22
Study 25213055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 22907440 — intervention group
Group type: EXPERIMENTAL
Intervention: Prokinetic with split-dose PEG (100 mg itopride administered twice with each split-dose of PEG)
Number of subjects: 0
Study 22907440 — intervention group
Group type: COMPARATOR
Intervention: Split-dose PEG alone
Number of subjects: 0
Study 20471311 — intervention group
Group type: EXPERIMENTAL
Intervention: IdentEvent™ seizure detection system
Number of subjects: 102
Study 20471311 — intervention group
Group type: COMPARATOR
Intervention: Persyst's Reveal® (three parameter settings)
Number of subjects: 102
Study 18767583 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at corresponding channel points (Gallbladder Channel and Bladder Channel)
Number of subjects: 165
Study 18767583 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture at routinely selected acupoints
Number of subjects: 165
Study 15981676 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease (n=26)
Number of subjects: 51
Study 15981676 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple system atrophy (n=11)
Number of subjects: 51
Study 12921618 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified anti-shock programme (urine output maintained at 100 ml/h)
Number of subjects: 34
Study 12921618 — intervention group
Group type: COMPARATOR
Intervention: Traditional resuscitation formula (urine output maintained at 40 ml/h)
Number of subjects: 34
Study 12921618 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 12575374 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zhengtian Pill (NZTP)
Number of subjects: 68
Study 12575374 — intervention group
Group type: COMPARATOR
Intervention: Fuguiqin Capsule (Control)
Number of subjects: 68
Study 12575374 — intervention group
Group type: COMPARATOR
Intervention: Healthy persons (comparison group)
Number of subjects: 68
Study 9364538 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2 for 1 hour every 3 weeks)
Number of subjects: 200
Study 9364538 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin (12 mg/m2 every 6 weeks) plus Vinblastine (6 mg/m2 every 3 weeks)
Number of subjects: 200
Study 9364538 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 200
Study 9364538 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin/Vinblastine
Number of subjects: 200
Study 1540762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 480
Study 1540762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 3892293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms per kilogram of body weight, single oral dose)
Number of subjects: 30
Study 3892293 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (daily for eight days)
Number of subjects: 30
Study 3892293 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 3892293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin and Diethylcarbamazine
Number of subjects: 30
Study 31638970 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment and radiation for Oral Cancer
Number of subjects: 14
Study 31638970 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-treatment prior to specialist consultation
Number of subjects: 14
Study 31638970 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment initiation after confirmed diagnosis
Number of subjects: 14
Study 31638970 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial expenditure on treatment
Number of subjects: 14
Study 28891153 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-site depression collaborative care (delivered by depression care manager, pharmacist, and psychiatrist)
Number of subjects: 292
Study 28891153 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 292
Study 28891153 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-site depression collaborative care
Number of subjects: 292
Study 25802933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic elastomeric fabric orthosis (DEFO)
Number of subjects: 8
Study 25802933 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 24247022 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice daily)
Number of subjects: 66
Study 24247022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 22453581 — intervention group
Group type: EXPERIMENTAL
Intervention: clindamycin phosphate 1.2%/BPO 2.5% gel
Number of subjects: 458
Study 22453581 — intervention group
Group type: COMPARATOR
Intervention: individual active ingredients and vehicle
Number of subjects: 458
Study 22453581 — intervention group
Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 458
Study 20214078 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle retention time in acupuncture treatment
Number of subjects: 0
Study 20214078 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17323403 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac alone
Number of subjects: 979
Study 17323403 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac with PPI
Number of subjects: 979
Study 17323403 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI effect without stratification
Number of subjects: 979
Study 16249145 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical caffeine 10%
Number of subjects: 39
Study 16249145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 11878517 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 20
Study 9508672 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/d)
Number of subjects: 21
Study 9508672 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 healthy volunteers)
Number of subjects: 21
Study 7943519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligament augmentation device
Number of subjects: 60
Study 7943519 — intervention group
Group type: COMPARATOR
Intervention: Semitendinosus and gracilis tendons alone (Control)
Number of subjects: 60
Study 2852389 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 800 micrograms twice daily
Number of subjects: 19
Study 2852389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2024740 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural diamorphine 3 mg
Number of subjects: 20
Study 2024740 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg
Number of subjects: 20
Study 780038 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate
Number of subjects: 0
Study 780038 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 780038 — intervention group
Group type: COMPARATOR
Intervention: Fludrocortisone
Number of subjects: 0
Study 29746385 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume running (HVR - twelve sprints per over)
Number of subjects: 20
Study 29746385 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-volume running (MVR - six sprints per over)
Number of subjects: 20
Study 27780479 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Barrier System
Number of subjects: 300
Study 27780479 — intervention group
Group type: COMPARATOR
Intervention: Routine operating room atmospheric conditions (Control)
Number of subjects: 300
Study 25827659 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 30
Study 25827659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23549644 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 5372
Study 22352084 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement kickoff conference
Number of subjects: 187
Study 19346952 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat (200 mg TID)
Number of subjects: 30
Study 19346952 — intervention group
Group type: COMPARATOR
Intervention: No miglustat treatment (Control)
Number of subjects: 30
Study 16801588 — intervention group
Group type: EXPERIMENTAL
Intervention: Random HbA1c (A1C)
Number of subjects: 2820
Study 16801588 — intervention group
Group type: COMPARATOR
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 2820
Study 15338068 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg cimetidine i.v. + 0.1 mg/kg dimetindene i.v. 20 min before induction of anaesthesia (Group 1)
Number of subjects: 1149
Study 15338068 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/kg ranitidine i.v. + 0.1 mg/kg dimetindene i.v. 20 min before induction of anaesthesia (Group 2)
Number of subjects: 1149
Study 15338068 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine p.o. + 0.1 mg/kg dimetindene i.v. 1 to 2 h before induction of anaesthesia (Group 3)
Number of subjects: 1149
Study 15338068 — intervention group
Group type: COMPARATOR
Intervention: 20 ml saline solution i.v. 20 min before induction of anaesthesia (Control Group 4)
Number of subjects: 1149
Study 15338068 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anaesthesia (n = 443)
Number of subjects: 1149
Study 11206660 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational interventions for persons who were unemployed
Number of subjects: 218
Study 9039510 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 20
Study 9039510 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) + Oxandrolone (Ox) 0.0625 mg/kg/day po
Number of subjects: 20
Study 9039510 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) + Testosterone (T) 5 mg i.m. every 14 days
Number of subjects: 20
Study 7942486 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-convergence method for measuring effective regurgitant orifice area (ROA)
Number of subjects: 45
Study 7942486 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-convergence method for measuring effective ROA
Number of subjects: 45
Study 3066966 — intervention group
Group type: EXPERIMENTAL
Intervention: isoptin (10 mg)
Number of subjects: 35
Study 3066966 — intervention group
Group type: EXPERIMENTAL
Intervention: obsidan (5 mg)
Number of subjects: 35